SEC Censures OTC Link LLC & Imposes USD $575,000 Penalty for Regulation SCI Failures

Key Takeaways
- The SEC censured OTC Link LLC and ordered it to pay a USD $575,000 civil penalty for failing to establish, maintain, and enforce Regulation SCI policies and procedures for OTC Link ATS between August 2016 and March 2025.
- The central issue was not only the missing policies but the repeated failure to remediate deficiencies after Division of Examinations staff flagged them.
- Compliance teams should treat exam findings as binding remediation obligations with firm deadlines and clear accountability.
Deep Dive
The SEC censured OTC Link LLC and ordered it to pay a USD $575,000 civil penalty for failing to establish, maintain, and enforce Regulation SCI policies and procedures for OTC Link ATS between August 2016 and March 2025. The central issue was not only the missing policies but the repeated failure to remediate deficiencies after Division of Examinations staff flagged them. Compliance teams should treat exam findings as binding remediation obligations with firm deadlines and clear accountability.
The SEC found that OTC Link LLC violated Rules 1001(a)(1), 1001(a)(2), and 1001(a)(3) of Regulation SCI. The firm lacked written policies and procedures reasonably designed to ensure that SCI systems, and indirect SCI systems for security standards, had adequate capacity, integrity, resiliency, availability, and security. The gaps covered system security, access control, and application vulnerability management, testing, and remediation. Some required policies were never established, and others stayed in draft form without being finalized or enforced.
The enforcement posture is the key takeaway. Division of Examinations staff examined OTC Link ATS several times over the period and flagged the same kinds of deficiencies each time, yet the firm did not promptly remediate. The Enforcement Division's Cyber and Emerging Technologies Unit described this as "a disregard" for examination findings and the examination process, and said it justified a "meaningful penalty." The case shows that recurring, unremediated exam findings can become the basis for enforcement even when no specific market disruption or security incident is cited. OTC Link LLC neither admitted nor denied the findings and agreed to a cease-and-desist order, a censure, and the USD $575,000 civil penalty.
The violation period ran from August 2016 to March 2025, roughly nine years. This indicates that the SEC may look back across multiple exam cycles when assessing whether a firm responded appropriately. No new requirements or compliance deadlines were introduced, but the order restates existing expectations. Rule 1001(a)(2) requires minimum policies and procedures and periodic effectiveness reviews, and Rule 1001(a)(3) requires prompt action to remedy deficiencies.
Recommended actions for compliance professionals:
- Inventory all open regulatory exam findings, internal audit issues, and draft policies, and assign owners and target dates.
- Escalate findings that remain open across more than one exam cycle to senior management and the board or relevant risk committee.
- Confirm that Regulation SCI policies are finalized, approved, and operating, not only documented, particularly for security, access control, and vulnerability management, testing, and remediation.
- Verify that indirect SCI systems are in scope for security standards.
- Perform and document periodic effectiveness reviews of policies and procedures.
- Maintain evidence of remediation, such as validation testing and closure sign-offs.

